Nucleix

Nucleix is a global leader in developing cancer diagnostic panels based on epigenetic biomarkers. Backed by OrbiMed and other major investors, Nucleix offers a robust product pipeline for various cancer types. The company develops, manufactures, and markets non-invasive molecular cancer diagnostic tests, with sensitivity and specificity based on the identification of subtle changes in methylation patterns. Nucleix provides a urine test for monitoring bladder cancer, called the Bladder EpiCheck, and a blood test for the early detection of lung cancer, known as the Lung EpiCheck.